# Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

> **NCT00651651** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 450 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** budesonide/formoterol
- **DRUG:** budesonide
- **DRUG:** formoterol

## Key facts

- **NCT ID:** NCT00651651
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2003-09
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651651, "Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00651651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*